Literature DB >> 27855263

Disruption or Excision of Provirus as an Approach to HIV Cure.

Keith R Jerome1,2.   

Abstract

An effective approach to HIV cure will almost certainly require a combination of strategies, including some means of reducing the latent HIV reservoir. Because the integrated HIV provirus represents the major source of viral persistence and reactivation, one attractive approach is the direct targeting of provirus for disruption or excision using targeted endonucleases, such as CRISPR/Cas9, zinc finger nucleases, TAL effector nucleases, or meganucleases (homing endonucleases). This article highlights some of the challenges for successful endonuclease therapy for HIV, including optimization of enzyme activity and specificity, the possible emergence of viral resistance, and most importantly, efficient in vivo delivery of the enzymes to a sufficient portion of the latent reservoir.

Entities:  

Keywords:  CRISPR/Cas9; HIV cure; endonuclease; gene editing; gene therapy; provirus

Mesh:

Substances:

Year:  2016        PMID: 27855263      PMCID: PMC5144885          DOI: 10.1089/apc.2016.0232

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  30 in total

1.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Authors:  Amanda M Crooks; Rosalie Bateson; Anna B Cope; Noelle P Dahl; Morgan K Griggs; JoAnn D Kuruc; Cynthia L Gay; Joseph J Eron; David M Margolis; Ronald J Bosch; Nancie M Archin
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

2.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

3.  RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection.

Authors:  Wenhui Hu; Rafal Kaminski; Fan Yang; Yonggang Zhang; Laura Cosentino; Fang Li; Biao Luo; David Alvarez-Carbonell; Yoelvis Garcia-Mesa; Jonathan Karn; Xianming Mo; Kamel Khalili
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-21       Impact factor: 11.205

4.  CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape.

Authors:  Zhen Wang; Qinghua Pan; Patrick Gendron; Weijun Zhu; Fei Guo; Shan Cen; Mark A Wainberg; Chen Liang
Journal:  Cell Rep       Date:  2016-04-07       Impact factor: 9.423

5.  Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.

Authors:  Qi Zhou; Katharina M Uhlig; Anke Muth; Janine Kimpel; Camille Lévy; Robert C Münch; Janna Seifried; Anett Pfeiffer; Alexandra Trkola; Cheick Coulibaly; Dorothee von Laer; Winfried S Wels; Udo F Hartwig; Els Verhoeyen; Christian J Buchholz
Journal:  J Immunol       Date:  2015-07-31       Impact factor: 5.422

Review 6.  Cell and gene therapy strategies to eradicate HIV reservoirs.

Authors:  Chelsea Spragg; Harshana De Silva Feelixge; Keith R Jerome
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

7.  Coupling endonucleases with DNA end-processing enzymes to drive gene disruption.

Authors:  Michael T Certo; Kamila S Gwiazda; Ryan Kuhar; Blythe Sather; Gabrielle Curinga; Tyler Mandt; Michelle Brault; Abigail R Lambert; Sarah K Baxter; Kyle Jacoby; Byoung Y Ryu; Hans-Peter Kiem; Agnes Gouble; Frederic Paques; David J Rawlings; Andrew M Scharenberg
Journal:  Nat Methods       Date:  2012-09-02       Impact factor: 28.547

8.  Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

Authors:  Ya-Chi Ho; Liang Shan; Nina N Hosmane; Jeffrey Wang; Sarah B Laskey; Daniel I S Rosenbloom; Jun Lai; Joel N Blankson; Janet D Siliciano; Robert F Siliciano
Journal:  Cell       Date:  2013-10-24       Impact factor: 41.582

9.  Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach.

Authors:  Joshua T Schiffer; Dave A Swan; Daniel Stone; Keith R Jerome
Journal:  PLoS Comput Biol       Date:  2013-07-04       Impact factor: 4.475

10.  CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape.

Authors:  Gang Wang; Na Zhao; Ben Berkhout; Atze T Das
Journal:  Mol Ther       Date:  2016-01-22       Impact factor: 11.454

View more
  4 in total

Review 1.  Defective HIV-1 genomes and their potential impact on HIV pathogenesis.

Authors:  Jeffrey Kuniholm; Carolyn Coote; Andrew J Henderson
Journal:  Retrovirology       Date:  2022-06-28       Impact factor: 3.768

Review 2.  Elimination of infectious HIV DNA by CRISPR-Cas9.

Authors:  Atze T Das; Caroline S Binda; Ben Berkhout
Journal:  Curr Opin Virol       Date:  2019-08-23       Impact factor: 7.090

3.  Increased Efficiency for Biallelic Mutations of the CCR5 Gene by CRISPR-Cas9 Using Multiple Guide RNAs As a Novel Therapeutic Option for Human Immunodeficiency Virus.

Authors:  Dong Lin; Stefan H Scheller; Madeline M Robinson; Reza Izadpanah; Eckhard U Alt; Stephen E Braun
Journal:  CRISPR J       Date:  2021-02

4.  Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.

Authors:  Pavitra Roychoudhury; Harshana De Silva Feelixge; Daniel Reeves; Bryan T Mayer; Daniel Stone; Joshua T Schiffer; Keith R Jerome
Journal:  BMC Biol       Date:  2018-07-11       Impact factor: 7.364

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.